DNFD Regulatory Translation Requirements: The Complete Guide for Drugs and Medical Devices in Panamá

Name: Dirección Nacional de Farmacia y Drogas (National Directorate of Pharmacy and Drugs), DNFD — the medicines and health-products regulator inside the Ministerio de Salud (MINSA). The DNFD grants registro sanitario, operating licences for pharmacies, distributors, laboratories and droguerías, GMP certification, controlled-substances permits, pharmacovigilance oversight, and the excepción de registro sanitario that lets an investigational medicinal product enter the country (DNFD portal). Panamá does not operate a single unified health-products agency of the ANVISA or INVIMA type: authority is split across the DNFD, a separate MINSA device directorate, and the health-research regulator, and each desk has its own language practice.

Establishing statute: MINSA was created by Decreto de Gabinete 1 de 15 de enero de 1969, and its sanitary police powers derive from the Código Sanitario, Ley 66 de 10 de noviembre de 1947 — both cited as the legal foundation in the considerando of Decreto Ejecutivo 21 de 23 de abril de 2026. The operative medicines statute is Ley 419 de 1 de febrero de 2024, published in Gaceta Oficial 29962-A and corrected by fe de errata in Gaceta 29966-A of 7 February 2024, which subrogated Ley 1 de 10 de enero de 2001 and Ley 97 de 4 de octubre de 2019 (Ley 419; Lexology). It is reglamented by Decreto Ejecutivo 27 de 10 de mayo de 2024 — a single instrument of 836 articles published in Gaceta 30028-C (DE 27; Panamá Digital). Reliance-based recognition runs through Decreto Ejecutivo 2 de 7 de enero de 2025, as modified in 2025 (DE 2 de 2025).

Scope: The DNFD regulates medicines and other products for human health — market authorisation, licensing of establishments, GMP, controlled substances, pharmacovigilance, and the investigational-product registration exception. Medical devices sit with MINSA's separate device directorate under Ley 90 de 26 de diciembre de 2017, as modified by Ley 92 de 12 de septiembre de 2019, reglamented by Decreto Ejecutivo 490 de 4 de octubre de 2019, itself modified by Decreto Ejecutivo 616 de 13 de mayo de 2020 (MINSA device directorate page). Health research — including interventional clinical trials — is governed by Ley 84 de 14 de mayo de 2019 (MINSA text) as reglamented by DE 21 de 2026.

Website: https://dnfd.minsa.gob.pa — relaunched publicly in October 2025 as the consolidated source for normativas, registros sanitarios, trámites, comunicados and sanitary alerts, with modules for Seguimiento de Trámite, Solicitudes de Registros Sanitarios, Certificados de Intercambiabilidad, payments, Medicamentos de Venta Popular, "DNFD Digital (21 Trámites)" and a Sistema de Monografías y Prospectos (La Web de la Salud).

Printed contact point: farmacoterapiafyd@minsa.gob.pa, listed under Departamento De Farmacovigilancia De Medicamentos Y Otros Productos Para La Salud Humana → Sección de Farmacoterapia, phone 501-0305 (DNFD Contacto). The same page prints departmental inboxes for registration evaluation, modifications, bioequivalence, imports and lot release, licences, audit and legal advice; we reproduce only what that page prints and extrapolate nothing.

Current head of authority: Director Nacional — Uriel Pérez, who presented the relaunched DNFD portal in October 2025 (La Web de la Salud). The Minister of Health who signed both the 2025 WLA recognition decree and the 2026 research decree is Fernando Boyd Galindo, per the signature blocks of DE 2 de 2025 and DE 21 de 2026.

Adjacent bodies sharing responsibility. Panamá's architecture is deliberately distributed. Getting the language rule right requires knowing which desk the document lands on.

Two structural facts about DNFD filings that reshape translation project planning. First, a Panamanian lawyer files, not the sponsor: DE 27 Art. 19 requires the application to be presented mediante abogado, with the refrendo of the responsible farmacéutico idóneo and of the Colegio Nacional de Farmacéuticos — so our Spanish passes two Panamanian professional gatekeepers before a reviewer sees it. Second, submissions are digital: DE 27 Art. 16 requires filing through a "plataforma tecnológica por medio de un expediente digital" — FADDI (Farmacia y Drogas Digital), indexed at dnfd.minsa.gob.pa/faddi and rolled out module by module since 2023 (DNFD Comunicado 030-2023; DNFD Comunicado 083/2024; MINSA). The DNFD has also stated publicly that digitalisation is a step toward being benchmarked by WHO's Global Benchmarking Tool as a high-standard authority (MINSA) — a regulator under benchmarking tightens documentation discipline, it does not loosen it.

Contact points we will not invent. The MINSA research page names the CNBI and links to it but prints no email address or telephone number for the CNBI or for the accredited institutional committees; the only printed contact datum is the REGULAIPS inbox (Regulación de Investigación para la Salud). We route CNBI correspondence through RESEGIS and REGULAIPS. [UNVERIFIED - source silent] on any dedicated CNBI mailbox. Likewise, the Caja de Seguro Social (CSS) operates hospitals that host trials, but no CSS clinical-trial inbox is printed on an official page — [UNVERIFIED - source silent].

Panamá's language rule is not a single sentence. It is a layered regime: a statute-level default, a reglamento-level general clause, and roughly two dozen document-specific carve-outs. Reading only the default costs money; reading only the carve-outs earns an RFI.

Statutory anchor — Ley 419, Art. 33 (verbatim, medicines market access):

"Toda documentación que se presente, para la obtención del registro sanitario debe estar en español o debidamente traducida por un traductor público autorizado. En cuanto a los estudios clínicos, se aceptarán en el idioma inglés y su resumen debe ser presentado obligatoriamente en español."

Registration documentation must be in Spanish or translated by a traductor público autorizado; clinical studies are accepted in English with a mandatory Spanish summary (Ley 419 Art. 33). Panamá put the English-language acceptance of clinical studies in the statute itself — not in a reglamento, not in guidance, not in reviewer discretion. That is the strongest form of legal comfort available in Latin America on this question, and it anchors Section D.

Reglamento anchor — DE 27, Art. 220 (verbatim, general clause):

"Toda la documentación debe ser presentada en idioma castellano/español, los documentos oficiales escritos en idioma distinto deben presentarse con su respectiva traducción por un traductor público autorizado."

Source: DE 27 de 2024. Placement nuance we do not skip. Art. 220 sits in Capítulo XIX, Sección I ("Generalidades"), the chapter on post-approval modifications — not in the decree's opening general-provisions title. A maximalist reading treats it as decree-wide; a textualist reading confines it to modification filings. Our operating position is to treat Art. 220 as decree-wide for legal and administrative documents, because the cost of over-translating a poder is trivial. But Art. 220 cannot be read to override Ley 419 Art. 33 on clinical studies: a reglamento cannot narrow a statute, and Art. 30 of the same decree expressly confirms the English allowance.

Statutory anchor — DE 490, Art. 35 (verbatim, devices):

"En caso de que los documentos legales originales presentados sean en otro idioma distinto al español, deberán acompañarse de una traducción al idioma español realizada por un traductor público autorizado de la República de Panamá."

Source: DE 490 de 2019. Three words carry the article: "documentos legales originales." Art. 35 does not say all documents — it says legal documents, and it exempts catalogues from legalisation entirely.

Statutory anchor — DE 21 de 2026, Art. 85 (verbatim, clinical trials):

"Es indispensable que todos los documentos, remitidos para estos trámites oficiales, presenten su contenido en idioma español y en las mismas versiones a ser presentadas al comité de bioética."

Every document remitted for the official RESEGIS trámites must be in Spanish and in the same versions filed with the bioethics committee (DE 21 Art. 85). Version-parity is a language requirement in Panamá: filing v3.0 Spanish to RESEGIS while the committee holds v2.1 is a defect even if both translations are perfect.

Statutory anchor — DE 21 de 2026, Art. 52 (verbatim, informed consent):

"El documento del consentimiento informado debe ser redactado en idioma español, en un lenguaje sencillo y comprensible para el participante…"

Note the verb: "redactado" — drafted in Spanish, with a readability standard, not merely translated into Spanish (DE 21 Art. 52). A back-translated ICF that is grammatically Spanish but syntactically English fails this article. We treat the Panamá ICF as a readability-graded deliverable, not a translation deliverable.

Three doctrinal facts embedded in the framework. First, Spanish is a decision-and-use rule, not a general dossier rule: Panamá requires Spanish where a Panamanian reads the document to make a decision or to use the product safely — legal instruments, labels, inserts, informed consent, protocols, safety reports — and accepts English where the document is technical evidence a trained evaluator reads, provided a Spanish summary or Spanish-translated key element exists. Second, the device architecture is explicitly tiered: legal instruments → sworn Spanish; user-facing instructions → Spanish; engineering and service documentation → English acceptable (DE 490 Arts. 35, 36.7, 36.8, 41.1). Third, Panamá bans relabelling: Ley 419 Art. 37 states the label "podrá estar impreso en varios idiomas a la vez, siempre que uno sea el español. No se aceptará reetiquetado o sobreetiquetado" and DE 490 Art. 39 states "No se aceptará el re etiquetado o sobre etiquetado, en ninguno de los empaques para su uso en la República de Panamá." You cannot fix a translation error with a sticker in Panamá — which converts translation quality from a compliance line item into a manufacturing-schedule risk.

The ISO 15223-1 basis. DE 490 Art. 39 permits "símbolos y colores internacionalmente reconocidos siempre y cuando se aclare en el instructivo o inserto el texto descriptivo de los mismos." Recognised international symbols are permitted on the label if the IFU carries the Spanish descriptive text for each — and because Art. 36.8 requires that instructivo to be in Spanish for each device (expressly not for equipos biomédicos), the practical result is that a Spanish symbol glossary inside the Spanish IFU buys a low-text, symbol-driven carton. That is the clearest statutory basis for symbol-based labelling in Central America.

The one place Panamá accepts an English-only label. DE 21 de 2026, Art. 97 governs investigational-product labelling — identification, lot, expiry, storage and special warnings — and then states: "Se aceptará el etiquetado, en idioma español o simultáneamente en varios idiomas a la vez, siempre que uno de ellos sea español. En casos excepcionales, se aceptará en idioma inglés, sin necesidad del idioma español, previa justificación ante la Dirección Nacional de Farmacia y Drogas, garantizando información relevante del medicamento para el participante de la investigación, en idioma español." That is a genuine, written, English-only IMP-label pathway, conditioned on prior justification to the DNFD and on the participant-relevant information reaching the subject in Spanish by another route.

Document-by-document language table (medicines — DE 27 de 2024 and Ley 419; devices — DE 490; trials — DE 21 de 2026).

Central American harmonization overlay. Panamá is a COMIECO member and has adopted the RTCA suite by decree — pharmaceutical labelling (RTCA 11.01.02:04 via DE 849 de 2015), stability studies (11.01.04:10 via DE 850), analytical method validation (11.03.39:06 via DE 851), natural-product labelling (11.04.41:06 via DE 852), medicines quality verification (11.03.47:07 via DE 853), natural-products quality verification (11.03.56:09 via DE 854), hygienic products (71.03.37:07 via DE 855) and pharmaceutical GMP (11.03.42:07 via DE 267 de 2014) (DNFD decree index). Ley 419 Art. 29 pins validated analytical methods, finished-product specifications and labels/inserts "conforme al RTCA," aligned with RTCA 11.03.59:18. Spanish artwork built to RTCA travels into Panamá. Devices do not harmonize: Panamá built its own CCT/CVT architecture under DE 490, anchored to GHTF/IMDRF classification rather than to a Central American device RTCA.

The regime is layered by document class, not by document age. Panamá does not impose a fixed calendar-day currency limit on foreign certificates the way Perú (two-year rule) or Colombia (INVIMA one-year CFS rule) do — but DE 27 Art. 29.2 sets GMP certificate validity at 2 years, and the whole framework was rewritten between 2024 and 2026, so the operative currency risk in Panamá is citing a repealed instrument, not a stale certificate.

*Panamá reserves sworn translation for legal instruments, and channels it through one licensed professional category: the traductor público autorizado (TPA). The TPA is a state-licensed professional licensed by the Ministerio de Educación (MEDUCA) — not by a translators' association, not by a court, and not by self-certification. The governing instrument is Decreto Ejecutivo 975 de 15 de diciembre de 2017, which subrogated Decreto Ejecutivo 472 de 11 de junio de 2014 ([MEDUCA text of DE 975](https://www.meduca.gob.pa/wp-content/uploads/2025/04/DECRETOS-975.pdf)), reglamented by Resuelto No. 2448 de 21 de mayo de 2018 ([MEDUCA text](https://www.meduca.gob.pa/wp-content/uploads/2025/01/RESUELTOS-2448-QUE-REGLAMENTA-L-DECRETO-EJECUTIVO-N%C2%B0975-DE-15-DIC.-DE-2017-QUE-SUBROGA-EL-DEC.pdf)), which grounds the regime in the Código Administrativo, Título XVII, as reformed by Ley 59 de 31 de julio de 1998. Licensing requirements are published at [MEDUCA's requisitos page](https://www.meduca.gob.pa/wp-content/uploads/2025/01/REQUISITOS-PARA-LA-LICENCIA-DE-TRADUCTOR-PUBLICO-AUTORIZADO-2017.pdf), and licences are granted by resolución published in the Gaceta Oficial*.

Tier table.

The commercially decisive line is the third row. Panamá's statute demands a Spanish resumen of clinical studies — and nowhere requires that resumen to be sworn. A well-drafted, technically accurate, unsworn Spanish summary satisfies Ley 419 Art. 33 on its face. That is the entire economic argument of Section D.

Three practical consequences of the TPA regime. First, a TPA is licensed per language pair — an English→Spanish TPA cannot swear a German→Spanish translation, so a dossier holding a German notified-body certificate, a French sterilisation validation and a Japanese CoA needs three licensed professionals, not one vendor stamp. Second, Panamá-licensed, not foreign-sworn: DE 490 Art. 35 says "un traductor público autorizado de la República de Panamá" and DE 27 Art. 28.3 says "un traductor público autorizado en Panamá" — a Spanish traductor jurado, a US ATA-certified translator or a Colombian traductor oficial is not substitutable on the face of the text. Third, signature registration is a separate step with MIRE for some cross-border chains (MIRE).

Apostille sequencing. Panamá is a Hague Apostille Convention party: the Convention was approved domestically by Ley 6 de 25 de junio de 1990, published in Gaceta Oficial 21571 of 3 July 1990 (Justia Panamá text), reglamented by Decreto Ejecutivo 445 de 12 de noviembre de 1991. DE 490 Art. 35 requires foreign documents for CCT/CVT and operating licences to be authenticated "conforme a las disposiciones del Convenio de Apostille, aprobado mediante Ley No. 6 del 25 de junio de 1990," with non-Hague origins routed through consular/MIRE legalisation and catalogues exempt. DE 27 Art. 216 requires all foreign legal documentation to be authenticated or apostilled and accepts electronic documents; Art. 28.8 expressly contemplates the apostilla electrónica. MINSA has issued dedicated guidance in DNFD Comunicado No. 21 de 28 de junio de 2023 and an explanatory Cápsula 7 — Apostilla. The DNFD charges B/.30.00 for Autenticación de Documentos (DNFD tarifa de trámites; DE 27 Art. 15).

The sequencing rule that trips foreign sponsors: obtain the signed original abroad, apostille it in the country of origin, and then have the Panamá TPA translate the document including the apostille certificate itself and every seal, stamp and marginal annotation — filing the apostilled original and the TPA translation as an annexed pair, because DE 27 Art. 28.3 is explicit that "esta traducción se anexará al certificado correspondiente." Translate first and apostille second, and the apostille attaches to a document the TPA never saw while the Spanish version omits the apostille text — reviewers cannot reconcile the two, and the translation is redone. Devices have a partial escape hatch: DE 490 Art. 43 allows a simple copy to be filed first with the apostilled original supplied within 3 meses — but the translation must ultimately match the final authenticated instrument.

The scheduling constraint nobody budgets for. TPA capacity in Panamá is finite. The population of MEDUCA-licensed English→Spanish public translators fluent in ISO 10993 biocompatibility language, IEC 60601 electrical-safety terminology and ICH E3 clinical-report structure is small (MEDUCA Traductores y Examinadores). Sworn translation in Panamá is therefore not merely expensive — it is a queue. Every page routed through a TPA that did not legally need to go there lengthens the critical path.

Amavita's 7th QC gate — Document Currency. Panamá is the LATAM jurisdiction where currency risk is highest, and it is instrument currency rather than certificate currency. Panamá rewrote its entire medicines framework between 2024 and 2026: Ley 419 de 2024 subrogated Ley 1 de 2001 and Ley 97 de 2019; DE 13 de 2023, DE 36 de 2020, DE 869 de 2021 and DE 112 de 2022 are marked DEROGADO on the DNFD decree index; DE 21 de 2026 Art. 104 repealed DE 1843 de 2014, DE 6 de 2015 and Resolución 390 de 2003; and DE 2 de 2025 was itself amended twice inside six months. Anyone working from a pre-2024 Panamá checklist is working from a dead document. Amavita Sciences™ therefore treats Panamá as a mandatory 7th-gate jurisdiction: every deliverable is re-checked against the live instrument list before release, every foreign document is timestamped at apostille, at translation and at filing, and a refreshed apostilled original triggers a fresh translation within 48 hours under our First-Pass Acceptance Program.

A preclinical package for a single drug or device program routinely runs 800–3,500 pages: pharmacology, PK/ADME, toxicology, safety pharmacology, biocompatibility, electrical safety, sterilisation validation, and their appendices. Panamá answers the translation question better than almost any other jurisdiction in the region — at statute level, in writing, with a named exception — for market access. For clinical trial authorization, the answer is narrower and, on the specific question of preclinical attachments, not yet written. This section is therefore deliberately split: full confidence on the market-access side, hedged on the clinical-trial side, with a formal consulta pending.

D.1 Do we have to translate every page of the preclinical stack?

The honest answer depends on which pathway the document is filed into, and Panamá's two pathways do not sit at the same level of legal certainty.

For market access / sanitary registration — full confidence. No.

Preclinical technical documentation does not require page-by-page Spanish translation for a Panamá sanitary registration or a Certificado de Criterio Técnico. Three provisions carry that conclusion, and the first is a statute.

• Ley 419, Art. 33 — registration documentation in Spanish or TPA-translated, but "en cuanto a los estudios clínicos, se aceptarán en el idioma inglés y su resumen debe ser presentado obligatoriamente en español." The English allowance for study evidence lives in the statute, not in a reviewer's discretion.
• DE 27, Art. 30 names the price of the allowance: "Se aceptará la presentación de estudios clínicos en inglés siempre que estén acompañados de un resumen en español de toda la evidencia clínica que demuestre el balance beneficio riesgo favorable." A substantive Spanish synthesis of the evidence base — not a cover note, not an abstract.
• Panamá's drug framework lists non-clinical evidence as a dossier item with no language rule attached. Ley 419 Art. 29 lists fourteen requisitos, including item 10, "Estudios de seguridad y eficacia" — no language qualifier. DE 27 Art. 102, the biologicals article, lists "4. Información de la fase preclínica" — no translation obligation. DE 27 Art. 155 requires "Estudios Toxicológicos" for homeopathics claiming a therapeutic indication — again with no language rule.

On the device side the silence is paired with an affirmative permission, which is stronger. DE 490 Art. 37 sets incremental requirements by class: Class B adds the sterilisation method; Class C adds a "Resumen de estudios o ensayos clínicos de seguridad y efectividad" plus a materials description; Class D adds risk analysis and mitigation, traceability protocols and "Información detallada de estudios clínicos y preclínicos de seguridad y efectividad" — with no Spanish-translation obligation attaching to any of it. Meanwhile Art. 36.7 affirmatively permits manufacturer technical literature in electronic or digital format with no language condition, Art. 41.1 affirmatively permits data sheets, product data and service manuals "en español o inglés," and Art. 35 confines the sworn-translation duty to "documentos legales originales."

Neither DE 490 nor Ley 419 / DE 27 contains any provision requiring page-by-page Spanish translation of ISO 10993 biocompatibility reports, IEC 60601 electrical-safety test reports, sterilisation-validation protocols and reports (ISO 11135 / 11137 / 17665), GLP animal-study reports, CB Test Certificates or Attestations of Test Results. On page-by-page translation of the preclinical stack, the Panamanian texts are silent — and that silence sits directly beside affirmative permissions for English technical documentation. [Note: the absence of an obligation is inferred from complete review of the operative decree texts cited above; no Panamanian instrument states an affirmative "preclinical need not be translated" rule.]

The strongest single confirmation is the reliance route. *[DE 2 de 2025, Art. 2(f)](https://www.minsa.gob.pa/sites/default/files/normatividad/decreto_ejecutivo_no_2_de_7_de_enero_de_2025_-_reconocimiento_de_registros_sanitarios_a_medicamentos_con_registros_de_la_oms.pdf) requires "una copia legalizada o apostillada del expediente completo del presentado en el país en donde se realizó el registro" — the complete foreign dossier — and imposes no translation obligation whatsoever. Panamá will accept an entire FDA- or EMA-tier dossier, in English, apostilled, with no sworn translation. `[UNVERIFIED - source silent]` on any Spanish-translation duty for the WLA expediente completo* within the four corners of DE 2.

The substitute, in one line: a Spanish executive summary per report plus a consolidated Spanish technical summary, with the English originals preserved and indexed — set out in full in D.3.

For clinical trial authorization (CNBI + MINSA REGULAIPS) — hedged, pending written confirmation.

We state our position on the trial pathway with less certainty than on market access, and we state why.

(a) The clinical protocol and the Investigator's Brochure must be in Spanish. DE 21 de 2026, Art. 85 imposes a general rule that "todos los documentos, remitidos para estos trámites oficiales, presenten su contenido en idioma español y en las mismas versiones a ser presentadas al comité de bioética," and Art. 84 requires the protocol and annexes in the same version filed with the ethics committee. On the medicines side, DE 27 Art. 213.2 requires the protocol and the ethics approval "en español y en formato electrónico." The Investigator's Brochure is named in DE 21 Art. 95 as the "Manual del investigador" without a document-specific language rule — so it sits inside the Art. 85 general Spanish rule, and we plan the trial-startup package on the basis that the IB is a Spanish deliverable.

(b) Preclinical technical documentation attached to the CTA may still be presented in English. Art. 95 attaches no explicit Spanish requirement to the technical annexes behind the IB, and the same article expressly permits English for comparator and concomitant-medication documentation: CPP, batch certificate or CFS "los cuales podrán ser presentados en idioma inglés o español, acompañados de un certificado de declaración de cumplimiento" (DE 21 Art. 95). DE 27 Art. 213.4 permits the investigational-product CoA "en idioma inglés o español." Panamá's reliance framework points the same way: DE 21 Art. 44 grants expedited review to studies "que cuentan con aprobación previa de un comité de ética de la investigación, en países y organizaciones internacionales regulatorias de alto estándar," Art. 71 sets the CNBI's normative frame as CIOMS, OMS-OPS, Helsinki, UNESCO and ICH GCP, and Art. 99 requires ICH GCP compliance for importation. A framework that keys itself to ICH GCP and to prior high-standard foreign approval is a framework built to read English technical evidence. Our stated position for Panamá is therefore: file English preclinical technical documentation behind a Spanish IB and Spanish executive summaries — and be prepared to produce more Spanish on request. But the honest characterisation is that the IB's technical annexes sit in tension between a document-specific silence in Art. 95 and a general Spanish rule in Art. 85, and we do not present that tension as resolved.

(c) A formal consulta is pending. Because the tension is textual rather than practical, we have not resolved it by inference. Amavita Sciences™ has filed a formal consulta with MINSA REGULAIPS requesting written confirmation of the preclinical translation scope for clinical trial authorization. Until a written response arrives, we scope trial-stage preclinical translation as a decision-ready range rather than a fixed number: Spanish executive summaries as the base case, full Spanish translation of the IB non-clinical section as the contingency, and English report bodies preserved either way.

D.2 If translation IS required — is it text-only or does it require desktop publishing (DTP)?

Where Panamá requires Spanish for a technical document, it requires format-faithful Spanish, and several provisions make that explicit rather than implied. Our posture is unchanged from the rest of our LATAM practice: text-only substance, no DTP for narrative summaries; DTP where the Spanish will be compared side-by-side against a source layout.

The rule we apply: if the Spanish document will be compared side-by-side against an English original by a reviewer, it is a DTP deliverable. If it will be read on its own as a synthesis, it is a text deliverable. Tables, labels, formulae, specifications and correction schedules are always the former. And because DE 490 Art. 44 requires corrections in donde dice / debe decir format, a Spanish deliverable produced as a linear text dump — table structure destroyed, source pagination bleeding into the Spanish body — is fatal twice over in Panamá: it breaks the fórmula cuali-cuantitativa table, and it makes the Art. 44 remediation route unusable.

D.3 If translation is NOT required — what substitutes for it?

Panamá names the substitute in its own words: a Spanish evidence layer. It has three components, and it is the same architecture we deploy across the region.

Component 1 — A Spanish executive summary per report (1–3 pages). For every English preclinical report in the file — each ISO 10993 biological-evaluation endpoint, each IEC 60601 test report, each sterilisation validation, each GLP toxicology study — a Spanish executive summary carrying: study identity and report number, test article identity and lot, standard and edition applied, laboratory and accreditation status, GLP / ISO 17025 status, methods in outline, acceptance criteria, results against those criteria, and an explicit pass/fail conclusion. This is the direct analogue of the resumen that DE 27 Art. 30 requires for clinical studies, applied to non-clinical evidence.

Component 2 — A consolidated Spanish technical summary. One Spanish document narrating the whole non-clinical programme and concluding on safety: biocompatibility conclusion, electrical and mechanical safety conclusion, sterility assurance conclusion, shelf-life conclusion, and a residual-risk statement tied to the risk analysis DE 490 Art. 37 requires for Class D. For medicines, this is the document that makes Ley 419 Art. 29 item 10 — "Estudios de seguridad y eficacia" — reviewable in Spanish without translating the underlying reports.

Component 3 — English originals preserved, with a Spanish index/concordance. The English report bodies stay in the file, unaltered, with a Spanish navigation table mapping each Spanish summary to the exact English report, its page range, and the requisito it satisfies. This is the artefact that makes English acceptable in practice: it converts a pile of English PDFs into a Spanish-navigable evidence file. It also pre-empts the concordance check contemplated by DE 490 Art. 32, under which the evaluator checks the manufacturer's own website for consistency with the filing.

Why this is the right trade for a Class C/D device or an innovator medicine.

The terminology-risk row is the one sponsors underestimate. Every page translated unnecessarily is a page a reviewer can find a discrepancy in. In a regime where DE 490 Art. 43 obliges the applicant to keep every filed document current and to notify changes — and where substantial changes force a new Certificado de Criterio Técnico — a smaller Spanish surface area is a smaller lifetime maintenance liability.

The two regulatory pathways trigger different translation obligations

Panamá, like every LATAM regulator, operates two related but separate pathways for a sponsor's product: (1) clinical-trial authorization, which lets the investigational product enter a study on the sponsor's timeline; and (2) market-access / sanitary registration, which lets the commercial product be sold. The same preclinical report is treated differently depending on which pathway it supports — and in Panamá the two pathways also sit at different levels of legal certainty on preclinical scope.

The practical consequence: a sponsor who runs a Panamá trial and then registers the product should build the Spanish evidence layer once, at trial stage, and reuse it at registration. The trial-stage Spanish protocol, the trial-stage Spanish IB non-clinical summary and the trial-stage consolidated Spanish technical summary are most of what the registration filing needs. Sponsors who treat the two pathways as unrelated projects pay for the same Spanish twice.

D.4 Consolidated preclinical instruction table

D.5 Where the preclinical translation risk actually sits

The clinical-trial pathway carries more translation-scope risk than market access, and the asymmetry is textual, not anecdotal. On the market-access side the sponsor is protected by a statute — Ley 419 Art. 33 — plus a confirming reglamento article, plus a reliance decree that accepts an entire untranslated foreign dossier (DE 2 de 2025 Art. 2(f)), plus device articles that affirmatively name English as acceptable (DE 490 Arts. 36.7 / 41.1). On the clinical-trial side the sponsor faces a blanket Spanish rule — DE 21 de 2026 Art. 85, covering "todos los documentos, remitidos para estos trámites oficiales" — with only document-specific carve-outs for the CoA and comparator documentation in Art. 95. No statute grants the trial pathway an English allowance for technical evidence the way Ley 419 Art. 33 does for registration. Scope the trial-stage preclinical translation with a contingency; scope the registration-stage preclinical translation without one.

Beyond that structural asymmetry, five failure modes, in descending order of realised cost:

1. The Spanish summary being thin. DE 27 Art. 30 demands a summary "de toda la evidencia clínica que demuestre el balance beneficio riesgo favorable." A three-paragraph abstract does not discharge that. If the summary is weak, the reviewer's cheapest remedy is to ask for the full Spanish translation — and the entire exemption is lost. The summary is the exemption. Fund it accordingly.
2. Version drift against the ethics file. DE 21 Art. 85 requires the RESEGIS versions to be the same versions filed with the bioethics committee. Preclinical data summarised from IB v6 while the committee holds IB v5 is a documented defect.
3. Legal-instrument misclassification. Whether a CB Test Certificate or an ISO 13485 certificate is a "documento legal original" under DE 490 Art. 35 is where sponsors guess. Guessing low costs an RFI; guessing high costs TPA fees. Our default: anything issued by a notified body, competent authority or accreditation body, bearing a signature and seal, is treated as a legal instrument. Test reports issued by a laboratory are not.
4. Apostille / translation sequencing. DE 490 Art. 43's three-month window for producing the apostilled original is a real trap, because the translation must ultimately match the apostilled instrument, not the draft.
5. Structural destruction in the Spanish deliverable. Compounded in Panamá by the relabelling ban: a table-destroying Spanish deliverable that reaches artwork cannot be fixed with a sticker (Ley 419 Art. 37; DE 490 Art. 39).

D.6 The institutional-committee layer that DE 21 does not fully expose

DE 21/2026 sits on top of an institutional-committee layer that carries most of the operational translation burden — and that layer is where the CBI, not the CNBI, sets the rules that a sponsor must actually meet. Two DE 21 articles turn each accredited committee's own procedure into binding law:

DE 21 Art. 32 — CNBI approves each CBI's operating procedure at accreditation, including its fee schedule and, by extension, its document and language requirements. An institutional rule inside an approved procedure has the same practical binding force as the national decree.

DE 21 Arts. 14–19 and Art. 37 — only CBIs accredited by CNBI may operate in the national territory. First accreditation runs up to 11 months; subsequent accreditations up to 3 years; each accreditation type has defined scope. The consequence is that "the CBI's rule" is not optional local color — it is enforced by CNBI's power to withdraw accreditation.

The reference institutional committee is CBI-ICGES, the bioethics committee of the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES). Its current requirements document, Requisitos de Presentación Inicial de Protocolos CBI-ICGES v11 dated 7 November 2025, contains the strongest translation clause published anywhere in Central America:

"Todos los documentos que se presentan para evaluación al CBI-ICGES deben estar en idioma español. En el caso de que el documento original se encuentre en inglés, deberá también presentarse el original, en su idioma y la traducción deberá ser certificada por personal idóneo para garantizar la calidad de la información y que no haya retrasos en la evaluación por parte del Comité."

And, unusually for LATAM, it puts the rule directly on the Investigator's Brochure — the main preclinical carrier:

"Manuales del investigador ('Investigator Brochure') en el idioma original y en castellano."

Its digital-submission list also imposes bilingual protocol filing: "Protocolos (versión en inglés u otro idioma y español), incluyendo anexos y material de soporte."

Operational reading for sponsors:

1. At CNBI / national level, DE 21 does not impose a general Spanish-language rule on the IB or on preclinical support reports. The DE 21 language rules are limited to (a) the ICF in Spanish (Art. 52), (b) all RESEGIS documents in Spanish and version-matched to the ethics-committee set (Art. 85), and (c) narrow English carve-outs for comparator/concomitant-product certificates (Art. 95) and exceptional labelling (Art. 97).
2. At institutional level, CBI-ICGES requires the IB and the protocol in the original language and in Castilian, with the translation "certified by suitably qualified personnel." "Personal idóneo" is not defined in the CBI-ICGES document, but the operative effect is: uncertified translations are flagged as a source of evaluation delay, so the sponsor either presents a translation the committee will accept or absorbs a resubmission cycle.
3. The CNBI's own posted 2016-era Procedimiento — predating both Ley 84 and DE 21/2026 — also puts a bilingual language rule on the IB: "c) Folleto o manual del investigador. En idioma original y en español. d) Protocolo firmado por el Investigador Principal. En idioma original y en español." Its current standing is uncertain post-DE 21, but no fetched Panamanian instrument revokes it either, so it should be treated as an additional exposure line at the national committee.

What this means at file-planning stage. If the trial routes through CBI-ICGES (or any institutional CBI whose CNBI-approved procedure uses the same language), the sponsor cannot solve the preclinical translation problem with a Spanish executive summary at the DNFD/DE 27 layer. The Investigator's Brochure and its preclinical annex will need Spanish. The preclinical support reports themselves may still be filed in English behind the IB if the CBI's procedure is silent — the CBI-ICGES text does not extend to "material de soporte" for the IB in the same explicit way it extends to protocol material — but that reading is not universal, and the safe assumption is that any committee whose procedure follows the CBI-ICGES pattern will treat a Spanish IB body as the minimum.

Sources: CBI-ICGES Requisitos v11 (7 Nov 2025); CNBI Procedimiento (2016); DE 21 de 2026.

D.7 DE 21 Art. 102 — LATAM's only explicit preclinical GLP article

Panamá is the only Central-American jurisdiction that names GLP inside its research decree. DE 21 Art. 102 (verbatim):

"Animales de laboratorio o experimentación. Los proyectos de investigación para la salud, en que se utilicen animales de laboratorio o experimentación, deberán ser evaluados, previamente a su ejecución, por un comité de ética y bienestar animal, en aras de cumplir con la normativa nacional e internacional vigente en la materia. Cuando sea necesario realizar estudios preclínicos, los mismos se deberán realizar en arreglo a las buenas prácticas de laboratorio, de conformidad con el Consejo internacional de Armonización y demás organismos de cooperación técnica de referencia."

The article has two operative effects on translation planning:

1. It names ICH GCP and, by reference to ICH's cooperation-body ecosystem, aligns the ethics-committee reading of "preclinical" with an international standard set — which is what lets a sponsor argue, at the committee, that preclinical support reports filed under ISO 10993, IEC 60601, ISO 14971, OECD GLP and equivalent instruments are acceptable in their original English body with a Spanish IB carrying the substantive results.
2. It creates a second review hop for any animal-model study: a comité de ética y bienestar animal must approve the animal work before execution. That committee's document requirements will vary — but where the animal-ethics committee sits inside an accredited CBI, the CBI's language rule (see D.6) will govern its input documents.

The practical planning consequence is that Panamá is the LATAM country where "preclinical" is normatively distinguished from "clinical" at the decree layer, which is the argument space in which the base-case (English preclinical bodies + Spanish IB summary) becomes defensible — provided the sponsor's IB itself is filed in Spanish per the institutional-committee rule.

Source: DE 21 de 2026, Art. 102.

Consulta pending. Amavita Sciences™ has filed a formal consulta with MINSA REGULAIPS (regulaips@minsa.gob.pa) requesting written confirmation of the preclinical translation scope for clinical trial authorization in Panamá. This section will be revised upon receipt of a written response.

D1. Drug market access — DNFD pathway

Governing instruments.

• Ley 419 de 1 de febrero de 2024 — regulates medicines and other products for human health; subrogated Ley 1 de 2001 and Ley 97 de 2019 (Ley 419)
• Decreto Ejecutivo 27 de 10 de mayo de 2024 — the 836-article reglamento (DE 27; Gaceta 30028-C)
• Decreto Ejecutivo 2 de 7 de enero de 2025 — WHO-Listed Authority recognition, as modified by DE 4 de 5 de febrero de 2025 and DE 12 de 25 de junio de 2025 (DE 2; DNFD decree index)
• Decreto Ejecutivo 29 de 28 de junio de 2023 — abbreviated-procedure requirements and the updated high-standard authority list (DNFD decree index)
• RTCA 11.03.59:18 dossier alignment via Ley 419 Art. 29; RTCA 11.01.02:04 labelling and RTCA 11.03.42:07 GMP adopted by decree (DNFD decree index)
• MINSA's own procedural Guía sobre el procedimiento para el registro sanitario

Registration modalities — and the translation load differs sharply between them.

Language and translation stack.

• Product labelling and insert: Spanish among the languages, per RTCA; no relabelling or over-labelling (Ley 419 Art. 37; DE 27 Art. 46).
• Certificado de libre venta: apostilled + sworn TPA translation annexed to the certificate (DE 27 Arts. 28.3 / 28.8).
• GMP certificate: "traducido al idioma español y debidamente legalizado" (DE 27 Arts. 77.3 / 78.3); validity 2 years, notarial copies accepted where the authority publishes GMP electronically (Art. 29.2).
• Fórmula cuali-cuantitativa: official translation where foreign-language, table preserved (DE 27 Art. 124.7).
• Clinical studies: English accepted with a mandatory Spanish summary of all clinical evidence (Ley 419 Art. 33; DE 27 Art. 30) — and DE 27 Art. 32 eliminates clinical studies entirely for multi-source products supported by fichas técnicas from high-standard regulators.
• Preclinical evidence: listed without a language rule (Ley 419 Art. 29 item 10; DE 27 Arts. 102 / 155).

Fees (DE 27 Art. 15 and the DNFD tarifa page; B/. = USD 1:1).

Two of those lines deserve emphasis. Clinical-trial IMP authorisation is free in Panamá, and so is the patient-level registration exception. Panamá is not monetising research entry — which means a sponsor's real cost of entering Panamá is almost entirely documentation and translation, not government fees. That is precisely the cost line a disciplined language strategy compresses.

Reliance / recognition. DE 2 de 2025 creates a recognition pathway for WHO-Listed Authority registrations with no prior laboratory analysis, a DNFD response in 10 días hábiles (Art. 3), a single RFI via FADDI (Art. 4), 5 días hábiles to cure (Art. 5), and assignment of the registration number within a maximum of 10 días hábiles (Art. 7), with post-market inspection powers under Art. 8. The government framed the end-to-end trámite as "no más de 10 días hábiles" (MEF; Presidencia). One caution: because DE 2 keys off the WHO list rather than naming FDA and EMA, Panamanian press flagged exposure if the United States withdrew from WHO (La Estrella de Panamá). Verify current list status before committing to that pathway.

Other market-access mechanics that touch language. Ley 419 Art. 30 requires the DNFD to publish applications so third parties may oppose on test-data grounds — the published application is a document competitors read. Ley 419 Art. 34 accepts the German, Argentine, British, US (USP/USP-NF), Spanish, European, French, Swiss, International, Japanese, Mexican and Chinese pharmacopoeias plus FCC, AOAC, Micromedex, Drug Information and Martindale, and permits use of a WHO-listed stringent authority's published monograph — another English-acceptance channel. DE 27 Art. 39 permits abbreviated-route medicines to be marketed while post-registration quality analysis is processed within six months.

D2. Drug regulatory submissions

Base dossier (Ley 419 Art. 29 + DE 27 procedural articles), with the language status of each item.

1. Power of attorney to a Panamá-resident representative — legalised; TPA if foreign-language (Ley 419 Art. 29)
2. CPP-OMS or CLV + GMP certificate — apostilled; CLV with sworn Spanish annexed (DE 27 Arts. 28.3 / 28.8 / 216)
3. Manufacturing contract where applicable
4. Fórmula cuali-cuantitativa — official translation if foreign-language (DE 27 Art. 124.7)
5. Monograph — a WHO-listed authority's published monograph is usable (Ley 419 Art. 34)
6. Validated analytical methods per RTCA
7. Finished-product specifications
8. Labels and insert per RTCA — Spanish artwork, print-ready, no relabelling
9. Stability-study report — climatic zone IVb on the WLA route (DE 2 Art. 2)
10. Safety and efficacy studies — no language rule attaches (Ley 419 Art. 29)
11. Analytical standards
12. Samples for laboratory analysis
13. Certificado de análisis — English or Spanish (DE 27 Art. 27.15)
14. Fee (DE 27 Art. 15)

Post-registration modifications. Chapter XIX of DE 27 governs post-approval change, and Art. 220's general Spanish clause textually sits there — so for modification filings the maximalist reading is unambiguous: everything in Spanish, foreign-language official documents with TPA translation. Fee B/.200 per modification. No modifications are accepted in the 6 months before expiry (Art. 219), and approved modifications must be implemented within 12 months (Art. 221).

Renewal cadence. Registro sanitario is valid 5 years, renewable (Ley 419 Art. 48); renewal non-compliance gives 3 meses to cure (DE 27 Art. 240); and where the product is not yet marketed, the renewal filing must include draft primary/secondary packaging and insert artwork "en idioma español" (Art. 234).

Pharmacovigilance obligations — the most language-prescriptive area of the entire framework, and asymmetric in a way that saves money if read precisely.

Art. 331 belongs in every Panamá scope of work. A 400-page PBRER stays in English; a six-page executive summary goes to a sworn translator. That is a roughly 98% reduction in sworn-translation volume for the single largest recurring regulatory document in a product's lifecycle — and it is the template for how Panamá thinks about technical evidence generally.

DNFD inside trial oversight. DE 27 Arts. 337–342 place the DNFD inside clinical-trial oversight: it participates in GCP inspections, evaluates protocols and authorises the investigational-product registration exception using ICH and high-standard-authority guidance. Art. 340 lets it require the CoA, formulation, labelling, stability studies, informed-consent forms, ADR reports and diethylene/ethylene glycol negativity tests; Art. 341 lets it request the DSUR; Art. 342 governs post-trial access importation, again requiring the protocol "en español y en formato electrónico."

D3. Drug clinical trials

Authorization architecture. Panamá applies a parallel-authorization model, not a sequential one. DE 21 Arts. 88–92 classify human interventional trials as alto riesgo and have MINSA technical units evaluate them in parallel with ethics review, with Art. 90 bringing the DNFD and other MINSA normative bodies into that evaluation. The governing stack is Ley 84 de 2019 + DE 21 de 2026 + DE 27 Arts. 209–214 and 337–342.

Ethics review. DE 21 Art. 44: ordinary review max 20 días hábiles; expedited max 10 días hábiles; exemption max 5 días hábiles — and expedited review is granted to minimal-risk studies and to studies "que cuentan con aprobación previa de un comité de ética de la investigación, en países y organizaciones internacionales regulatorias de alto estándar." Art. 45 caps total ethics review at 30 días hábiles (+10 if returned to the pleno), gives the investigator 20 días hábiles to respond, and requires the certificate within 3 días hábiles. Decisions are Aprobación, modificaciones mínimas, modificaciones mayores, or Rechazo. Art. 46 allows a multicentre study to be approved by a single accredited CBI — one committee, one Spanish document set, version-controlled.

Registration. Via RESEGIS (DE 21 Arts. 82–86): Art. 84 requires the protocol and annexes in the same version filed with the committee, Art. 85 imposes the Spanish-and-version-parity rule, and Art. 86 produces a registration receipt within 3 días hábiles. MINSA publishes RESEGIS access, file-upload, tramitantes and CNBI/CBI follow-up guides, plus quarterly RESEGIS activity reports currently through Q2 2026, on the research regulation page.

IMP evaluation. DE 21 Art. 95: via RESEGIS the sponsor files GMP certificates of the IMP or a QP GMP declaration or equivalents, the certificado de análisis, the Manual del investigador, and other protocol-cited manuals such as the pharmacy manual and study-procedures manual; comparator and concomitant-medication CPP, batch certificate or CFS "podrán ser presentados en idioma inglés o español, acompañados de un certificado de declaración de cumplimiento"; and the DNFD responds "en un plazo no superior a quince días hábiles." Importation under Art. 99 rests on RESEGIS registration + ethics approval + DNFD authorisation, with ICH GCP compliance required. Safety reporting and joint GCP inspections are coordinated between the DGSP, the CNBI and the DNFD under Art. 96. The parallel medicines-side route is the excepción de registro sanitario under DE 27 Art. 213, valid 60 días hábiles for importation with no extension (Art. 214).

The Panamá trial-startup translation package, minimally scoped.

E1. Device market access — DNFD/MINSA device directorate pathway

Governing instruments.

• Ley 90 de 26 de diciembre de 2017, as modified by Ley 92 de 12 de septiembre de 2019 (MINSA device directorate page)
• Decreto Ejecutivo 490 de 4 de octubre de 2019 — the operative reglamento, published in Gaceta Oficial 28875-A, modified by DE 616 de 13 de mayo de 2020
• Decreto Ejecutivo 48 de 12 de abril de 2022 — donations of medicines, medical devices, biomedical equipment and medical furniture, repealing DE 988 de 2015 (DNFD decree index)
• A practitioner overview of the process is published by the US Commercial Service

The architecture is unusual, and it shapes what needs translating. Instead of a classic registro sanitario, DE 490 built the device system around a Certificado de Criterio Técnico (CCT) and a Certificado de Verificación Técnica (CVT) issued by the device directorate. Under DE 490 Art. 21 the CCT is valid for five years and — unusually for the region — is issued at no cost. Devices are not RTCA-harmonised: where drugs ride the Central American technical regulations, devices ride DE 490 plus GHTF/IMDRF classification principles (DE 490 Art. 30).

Classification (DE 490 Art. 30). Four risk classes — A (low), B (low-moderate), C (moderate-high), D (high) — assigned per GHTF/IMDRF criteria. Product families are coded under Art. 22 using the directorate's family prefixes: MQ (material médico-quirúrgico), EB (equipo biomédico), IMA (implantes), LAB (laboratorio), ODO (odontología) and OT (otros).

Class-incremental technical requirements (DE 490 Art. 37). Class B adds the sterilisation method; Class C adds a "Resumen de estudios"; Class D adds detailed clinical and preclinical information. This is the single most important article for translation scoping, and it is worth being precise about what it does not say: Art. 37 attaches no language rule to any of these three increments. The obligation is to supply the information, not to supply it in Spanish.

Language and translation stack — devices.

Read together, Arts. 36.7, 37 and 41.1 are the most permissive device-side technical-language provisions in Central America. We treat them as the operative authority for scoping: the patient- and operator-facing surface (IFU, labels, warnings) is a Spanish deliverable with print-fidelity consequences, and the engineering surface (test reports, service manuals, data sheets, technical literature) is not.

Authentication and correction mechanics. Art. 43 allows a simple copy to be filed first, with the apostilled original delivered within 3 meses; a substantial change to the device requires a new CCT rather than an amendment. Art. 44 requires corrections to be filed in the "donde dice / debe decir" format — a two-column correction instrument that is itself a translation deliverable when the underlying document is foreign. Under Art. 32, the evaluator checks the manufacturer's own website for concordance with the filed dossier, which means a Spanish IFU that diverges from the manufacturer's published English IFU is a self-inflicted RFI. Art. 42 sets out the heightened-scrutiny triggers.

Procedural clocks (DE 490 Art. 24). Decision within 30 días hábiles; RFI response within 60 días hábiles, extendable by a further 30; non-response is treated as desistimiento — the file is abandoned, not merely delayed.

Establishment licensing and fees. The licencia de operación runs 5 years (Art. 13) and renewal must be filed 60 días hábiles before expiry (Art. 26). Fees under Art. 64: B/.350 fabricante, B/.225 acondicionador, B/.200 distribuidor, B/.150 minorista/almacén, B/.25 actualización. The balboa is pegged 1:1 to the U.S. dollar, so these are dollar figures.

Pending replacement decree — currency risk on the device side is live. MINSA put a replacement device decree out for public consultation from October 2025 to February 2026 (MINSA consultation notice); the draft text circulated through the Cámara de Comercio and was analysed by AARSA. As of this writing it is not promulgated, and DE 490 remains the governing instrument. We do not scope device translation to the draft. We do timestamp every device deliverable so that, if the replacement decree is promulgated, the sponsor knows precisely which filings were built on DE 490 language provisions. The original 2019 framework and its practical effect were summarised at the time by Dentons, and the registration process is described for exporters by the US Commercial Service.

E2. Device regulatory submissions

Base dossier. The CCT dossier under DE 490 Arts. 35–41 assembles four blocks, and each block has a different translation instruction:

1. Legal block — company documents, power of attorney, manufacturer authorisation, Certificate of Free Sale or equivalent authority certificate. Apostilled per Ley 6 de 25 de junio de 1990 then sworn-translated by a Panamá traductor público autorizado (Art. 35).
2. Technical block — manufacturer technical literature, data sheets, product data, service manuals, test reports. Electronic/digital acceptable, no Spanish duty (Arts. 36.7, 41.1).
3. Class-increment block — sterilisation method (B), resumen de estudios (C), detailed clinical and preclinical information (D). Content duty only (Art. 37).
4. User-facing block — IFU, inserts, labels, symbology. Spanish, print-fidelity, no relabelling (Arts. 36.8, 38, 39).

What we actually deliver on a Class C or Class D device file.

*The Class C "Resumen de estudios" is the highest-leverage sentence in the Panamá device framework. [Art. 37](https://www.gacetaoficial.gob.pa/pdfTemp/28875_A/GacetaNo_28875a_20191004.pdf) asks a Class C applicant for a summary of studies — not the studies themselves, and not a translation of them. A well-built Spanish resumen de estudios discharges the requirement while the underlying ISO 10993 and IEC 60601 report bodies stay in English. A thin or generic resumen* invites the evaluator to ask for the underlying reports, and once they are requested in Spanish the sponsor has lost an exemption it never had to lose. This is the summary-insufficiency defect class, and on the device side it is where we see it most often.

Post-market surveillance. Device tecnovigilancia obligations attach to the establishment holding the licencia de operación under DE 490; donations of medical devices, biomedical equipment and medical furniture are separately regulated by Decreto Ejecutivo 48 de 12 de abril de 2022, which repealed DE 988 de 2015 (DNFD decree index).

E3. Device clinical trials

This is the thinnest surface in the Panamá framework, and we say so rather than filling the gap with inference. Decreto Ejecutivo 21 de 23 de abril de 2026 rebuilt the health-research and bioethics architecture for Panamá, and its ethics-review machinery is device-agnostic: an interventional device study is an investigación de alto riesgo reviewed by an accredited comité de bioética under Art. 44 and registered in RESEGIS under Arts. 82–86 on exactly the same terms as a drug study. The Spanish-language obligations therefore bite identically:

• The informed consent form must be drafted in Spanish, in plain and comprehensible language — DE 21 Art. 52 ("Idioma") requires the ICF "debe ser redactado en idioma español, en un lenguaje sencillo y comprensible." This is a drafting standard, not a translation standard.
• All documents filed for the RESEGIS trámite must be in Spanish and in the same versions filed with the ethics committee — DE 21 Art. 85: "Es indispensable que todos los documentos, remitidos para estos trámites oficiales, presenten su contenido en idioma español y en las mismas versiones a ser presentadas al comité de bioética."
• MINSA technical review runs in parallel with ethics review for high-risk interventional studies (DE 21 Arts. 88–92), which compresses the translation calendar rather than sequencing it.

Where the framework goes silent. DE 21 Art. 95 — the article that sets the DNFD's 15 día hábil evaluation window and enumerates the investigational-product documents — is drafted for investigational medicines. It names GMP certificates or a Qualified Person GMP declaration, the certificado de análisis, the Manual del investigador, and protocol-cited manuals. *Whether the Dirección Nacional de Dispositivos Médicos formally evaluates investigational devices under DE 21 the way the DNFD evaluates investigational medicines is [UNVERIFIED - source silent]* — DE 21 Art. 95 does not name the device directorate, and no promulgated instrument on the MINSA normativas index supplies the device analogue. We flag it, we do not invent it, and we scope device trial-startup translation to the obligations that are actually written down: Spanish ICF, Spanish protocol and Spanish RESEGIS file with version parity, plus Spanish patient-facing materials.

Practical consequence for device sponsors. Because the device-side investigational-product pathway is not codified with the specificity of Art. 95, the sponsor carries more discretionary exposure than a drug sponsor does. Our posture is to build the Spanish protocol, ICF and RESEGIS package to the DE 21 standard, keep ISO 10993 / IEC 60601 / ISO 13485 evidence in English with Spanish executive summaries, and hold a Spanish consolidated technical summary in reserve so that a directorate request can be answered inside the DE 490 Art. 24 RFI window without a new translation cycle.

Amavita Sciences™ works six defect classes. Below, each is mapped onto the Panamá statutory surface that produces it, with the rejection language a sponsor should expect to read.

Three Panamá-specific traps worth naming separately.

The desistimiento cliff. On the device side, DE 490 Art. 24 treats non-response to an RFI as desistimiento — abandonment. On the medicines side, DE 27 Art. 22 gives 3 meses to cure a new registration and Art. 240 the same 3 meses on renewal. But the WLA-recognition route under DE 2 de 2025 Arts. 4–5 allows a single RFI with only 5 días hábiles to cure. A sponsor who wins the fastest pathway inherits the least forgiving clock, and translation capacity has to be pre-positioned before the RFI arrives, not sourced after.

The six-month modification freeze. DE 27 Art. 219 bars post-registration modifications in the 6 months before a registration expires. Sponsors who discover a labelling translation error late in the cycle cannot fix it by modification; they carry it into renewal.

The concordance check. DE 490 Art. 32 directs the evaluator to the manufacturer's own website. A Spanish IFU that says something the manufacturer's published English IFU does not say is a defect the sponsor manufactured itself.

Amavita's 7th QC gate — Document Currency — is the Panamá-specific control. Panamá rewrote its entire medicines framework in 2024, its recognition framework in 2025, its research and bioethics framework in April 2026, and has a device decree sitting in post-consultation limbo (MINSA consultation extension). No other Central American jurisdiction has moved this much statutory ground in twenty-four months. Our Document Currency gate timestamps every foreign document at three points — apostille issuance, translation delivery, and filing — and re-issues a corrected translation within 48 hours when a sponsor refreshes an underlying document under the First-Pass Acceptance Program at $2,500/business-day.

The Panamá timelines are short, and that is the problem. A 20 día hábil registration decision, a 15 día hábil DNFD investigational-product review, a 3 día hábil RESEGIS acknowledgement and a 5 día hábil WLA cure window are all faster than a conventional translation procurement cycle. In Panamá the translation stack has to be complete before the clock starts, because there is no version of this calendar in which a sponsor sources a sworn translation reactively and still holds the window.

2023 (June 28) — Apostille guidance reissued. MINSA publishes Comunicado No. 21 on apostille handling for health filings, reinforced by its Cápsula 7 — Apostilla explainer. Both documents remain the practical reference for how foreign public documents enter a Panamá health file.

*2023 — DNFD digital trámites consolidated. [Comunicado 030-2023](https://www.minsa.gob.pa/sites/default/files/publicacion-general/comunicado_030-2023_produccion_tramites_cvm_dc_imp.pdf) moves production trámites* for CVM, DC and IMP onto the directorate's digital channel — the precursor to the FADDI expediente.

2024 (February 1) — Ley 419 de 2024 enacted. The new Ley de Medicamentos is published in Gaceta Oficial 29962-A, replacing Ley 1 de 2001 and Ley 97 de 2019 (Ley 419). A fe de errata follows on 7 February 2024 in Gaceta 29966-A, recorded in the Procuraduría de la Administración normative registry. The statute's language rule is Art. 33; its labelling rule, including the prohibition on reetiquetado o sobreetiquetado, is Art. 37. Practitioner commentary at enactment is summarised on Lexology.

2024 (May 10) — Decreto Ejecutivo 27 de 2024 promulgated. The 836-article reglamento to Ley 419 is published in Gaceta Oficial 30028-C (full text) and signed at the Presidencia. It carries the general documentary-language rule at Art. 220, the clinical-evidence carve-out at Art. 30, the FADDI digital expediente at Art. 16, and a 12-month implementation runway at Art. 221.

*2024 (May 24) — DNFD industry conversatorio.* The directorate walks industry through the new framework; the presentation deck remains the clearest official summary of how DNFD intends to operate Ley 419 and DE 27 in practice.

2024 (September 9) — Therapeutic-indication certification procedure. Comunicado 094 sets out the trámite for certification of therapeutic indications.

2024 — FADDI extended to controlled substances. Comunicado 083/2024 launches the controlled-substances module on the FADDI platform, and the DNFD trains users on the platform through GMP/GSP sessions.

2025 (January 7) — Decreto Ejecutivo 2 de 2025: WLA recognition. Published in Gaceta 30195-A (full text), the decree creates a recognition pathway for medicines already registered by a WHO-Listed Authority. President Mulino signs it publicly (Presidencia; MEF; Telemetro). Its eight requirements at Art. 2 include a "copia legalizada o apostillada del expediente completo" and zone IVb stability data; *whether any Spanish-translation duty attaches to that expediente completo is [UNVERIFIED - source silent] — the decree does not say. Laboratory analysis is waived ([Art. 1](https://www.minsa.gob.pa/sites/default/files/normatividad/decreto_ejecutivo_no_2_de_7_de_enero_de_2025_-_reconocimiento_de_registros_sanitarios_a_medicamentos_con_registros_de_la_oms.pdf)), the DNFD answers in 10 días hábiles ([Art. 3](https://www.minsa.gob.pa/sites/default/files/normatividad/decreto_ejecutivo_no_2_de_7_de_enero_de_2025_-_reconocimiento_de_registros_sanitarios_a_medicamentos_con_registros_de_la_oms.pdf)), and a single RFI carries a 5 día hábil* cure window (Arts. 4–5). Firm analyses were published by Central Law and Salud y Fármacos.

2025 (February 5) and 2025 (June 25) — DE 2 amended twice. Decreto Ejecutivo 4 de 5 de febrero de 2025 and Decreto Ejecutivo 12 de 25 de junio de 2025 modify the recognition decree within six months of its promulgation (DNFD decree index) — a currency risk for any dossier assembled against the January text.

2025 — WLA reliance exposed to external shock. Panamá's reliance architecture depends on WHO listing; the domestic press flagged the risk to MINSA and to the medicines register when U.S. withdrawal from the WHO was announced (La Estrella de Panamá). Sponsors relying on DE 2 should hold a conventional Ley 419 filing package in reserve.

2025 — Abbreviated-procedure requirements clarified. Requirements for the procedimiento abreviado for new sanitary registrations are set out and analysed by Panamanian counsel, complementing DE 27 Arts. 17–18 and 24.

2025 (October) – 2026 (February) — Replacement device decree in public consultation. MINSA opens, then extends the public consultation for a new medical-device regulation. The draft text circulated through the Cámara de Comercio and was reviewed by AARSA. It is not promulgated. DE 490 de 2019 remains in force.

2025–2026 — DNFD digital consolidation. The directorate presents the impact of its digital transformation and consolidates registration, alerts and guidance onto a single public platform; the DNFD portal and its published tariff schedule are now the primary operational references. MINSA and Customs also sign a memorandum of understanding on sanitary surveillance of medicines.

2026 (April 23) — Decreto Ejecutivo 21 de 2026: health research and bioethics rebuilt. Published in Gaceta Oficial 30510-C (full text), reglamenting Títulos III and IV of Ley 84 de 2019. It makes the CNBI adscrito al Despacho Superior and functionally independent (Art. 1) with eleven members (Art. 3); adopts CIOMS, OMS-OPS, Helsinki, UNESCO, ICH GCP, Singapore, Montreal, Nuremberg and Belmont as reference standards (Art. 71); sets the ethics clocks at Arts. 44–45; requires a single accredited committee for multicentre studies (Art. 46); imposes the Spanish ICF drafting rule at Art. 52; builds RESEGIS at Arts. 82–86 with the Spanish-and-version-parity rule at Art. 85; and sets the DNFD investigational-product review at Art. 95. It entered into force on promulgation (Art. 105) and repealed the prior research instruments (Art. 104). MINSA's operational notices on the research pathway are consolidated on the REGULAIPS page, with directorate-level updates in Comunicado 158 and Comunicado 163.

What this means for a sponsor filing in 2026. Every translation memory, glossary, and template built against Panamá's pre-2024 framework is obsolete. The medicines rules changed in 2024, the recognition rules changed in 2025 and were amended twice, the research rules changed four months ago, and the device rules are mid-replacement. Panamá is the LATAM jurisdiction where the Document Currency gate earns its place in the pipeline.

• Adjacent Central American regulator, fully mapped: SRS regulatory translation requirements — the complete guide for El Salvador
• Preclinical translation across 9 LATAM regulators (includes the Panamá section): Preclinical translation requirements — 9 LATAM regulators
• Sworn vs certified vs simple translation across LATAM: Sworn vs certified translation — regulatory submissions
• Apostille-then-translate sequencing across Hague-Convention LATAM jurisdictions: Apostille sequencing — LATAM regulatory filings
• Spanish ICF readability standard: INFLESZ threshold — Spanish ICF readability
• RFI anatomy across LATAM regulators: RFI anatomy — six LATAM regulator rejections
• One-protocol-change amendment cascade: Amendment cascade — LATAM translation stack
• Three-band framework for LATAM translation: Three bands of LATAM regulatory translation
• Translation QC for regulatory dossiers: Translation QC — regulatory dossiers
• Costly translation mistakes across LATAM: Costly translation mistakes — regulatory submissions
• Platform vs traditional translation for LATAM regulators: Regulatory language infrastructure vs traditional translation